title: Differential loss of heterozygosity in familial, sporadic, and uremic hyperparathyroidism.
abstract: Various genetic loci harboring oncogenes, tumor suppressor genes, and genes for calcium receptors have been implicated in the development of parathyroid tumors. We have carried out loss of heterozygosity (LOH) studies in chromosomes 1p, 1q, 3q, 6q, 11q, 13q, 15q, and X in a total of 89 benign parathyroid tumors. Of these, 28 were sporadic parathyroid adenomas from patients with no family history of the disease, 41 were secondary parathyroid tumors, 5 were from patients with a history of previous irradiation to the neck, 12 were from patients with a family history of hyperparathyroidism, and 3 were parathyroid tumors related to multiple endocrine neoplasia type 1 (MEN1). In addition, we determined the chromosomal localization of a second putative calcium-sensing receptor, CaS, for inclusion in the LOH studies. Based on analysis of somatic cell hybrids and fluorescent in situ hybridization to metaphase chromsomes, the gene for CaS was mapped to chromosomal region 2q21-q22. The following results were obtained from the LOH studies: (1) out of the 24 tumors that showed LOH, only 4 had more than one chromosomal region involved, (2) in the tumors from uremic patients, LOH of chromosome 3q was detected in a subset of the tumors, (3) LOH of the MEN1 region at 11q13 was the most common abnormality found in both MEN1-related and sporadic parathyroid tumours but was not a feature of the other forms of parathyroid tumors, (4) LOH in 1p and 6q was not as frequent as previously reported, and (5) tumor suppressor genes in 1q and X might have played a role, particularly on the X chromosome, in the case of familial parathyroid adenomas. We therefore conclude that the tumorigenesis of familial, sporadic, and uremic hyperparathyroidism involves different genetic triggers in a non-progressive pattern.
authors.affiliation: Department of Molecular Medicine, Karolinska Hospital, Stockholm, Sweden. ffa@gen.ks.se
authors.forename: F
authors.initials: F
authors.lastname: Farnebo
authors.forename: B T
authors.initials: BT
authors.lastname: Teh
authors.forename: C
authors.initials: C
authors.lastname: Dotzenrath
authors.forename: W S
authors.initials: WS
authors.lastname: Wassif
authors.forename: A
authors.initials: A
authors.lastname: Svensson
authors.forename: I
authors.initials: I
authors.lastname: White
authors.forename: R
authors.initials: R
authors.lastname: Betz
authors.forename: P
authors.initials: P
authors.lastname: Goretzki
authors.forename: K
authors.initials: K
authors.lastname: Sandelin
authors.forename: L O
authors.initials: LO
authors.lastname: Farnebo
authors.forename: C
authors.initials: C
authors.lastname: Larsson
mesh_terms: D000236:Adenoma / Q000150:complications / Q000235:genetics; D001345:Autoradiography; D002135:Calcium-Binding Proteins / Q000235:genetics*; D002872:Chromosome Deletion; D002874:Chromosome Mapping; D002889:Chromosomes, Human, Pair 2; D005260:Female; D006579:Heterozygote; D006801:Humans; D006822:Hybrid Cells; D006961:Hyperparathyroidism / Q000150:complications / Q000235:genetics*; D006962:Hyperparathyroidism, Secondary / Q000235:genetics; D017404:In Situ Hybridization, Fluorescence; D008297:Male; D018761:Multiple Endocrine Neoplasia Type 1 / Q000150:complications / Q000235:genetics; D009369:Neoplasms / Q000235:genetics; D010282:Parathyroid Neoplasms / Q000150:complications / Q000235:genetics* / Q000556:secondary; D011973:Receptors, LDL / Q000235:genetics*; D014511:Uremia / Q000150:complications
chemical_list: D002135:Calcium-Binding Proteins; D011973:Receptors, LDL